Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded at ValuEngine

Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by equities research analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Friday, ValuEngine reports.

Several other research analysts also recently commented on the company. Guggenheim began coverage on Teva Pharmaceutical Industries in a research note on Thursday, September 12th. They issued a “neutral” rating for the company. Wolfe Research began coverage on Teva Pharmaceutical Industries in a research note on Friday, July 19th. They issued a “peer perform” rating and a $9.00 target price for the company. Morgan Stanley downgraded Teva Pharmaceutical Industries from an “equal weight” rating to an “underweight” rating and cut their target price for the stock from $16.00 to $6.00 in a research note on Monday, July 15th. Wells Fargo & Co cut their target price on Teva Pharmaceutical Industries from $17.00 to $8.00 and set a “market perform” rating for the company in a research note on Monday, September 30th. Finally, Raymond James cut their target price on Teva Pharmaceutical Industries from $22.00 to $15.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. Six research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $10.78.

Shares of TEVA stock traded up $0.83 on Friday, hitting $9.30. 34,192,717 shares of the stock were exchanged, compared to its average volume of 16,922,125. The company has a current ratio of 0.96, a quick ratio of 0.62 and a debt-to-equity ratio of 1.73. The firm has a market capitalization of $9.32 billion, a PE ratio of 3.32, a P/E/G ratio of 0.89 and a beta of 1.73. Teva Pharmaceutical Industries has a one year low of $6.07 and a one year high of $23.97. The firm’s 50 day moving average is $7.51 and its two-hundred day moving average is $8.90.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, August 7th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.02. The company had revenue of $4.34 billion during the quarter, compared to the consensus estimate of $4.25 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.04% and a negative net margin of 21.94%. The firm’s quarterly revenue was down 7.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.78 EPS. On average, sell-side analysts expect that Teva Pharmaceutical Industries will post 2.26 earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in TEVA. AdvisorNet Financial Inc raised its holdings in shares of Teva Pharmaceutical Industries by 71.3% in the 3rd quarter. AdvisorNet Financial Inc now owns 3,665 shares of the company’s stock valued at $25,000 after acquiring an additional 1,525 shares in the last quarter. First Interstate Bank purchased a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $28,000. Motco purchased a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at about $28,000. Lindbrook Capital LLC raised its holdings in shares of Teva Pharmaceutical Industries by 76.6% during the 3rd quarter. Lindbrook Capital LLC now owns 4,461 shares of the company’s stock valued at $31,000 after buying an additional 1,935 shares in the last quarter. Finally, Pacer Advisors Inc. purchased a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at about $32,000. 58.21% of the stock is currently owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Story: What is the S&P 500 Index?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.